First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study
- PMID: 22271702
- DOI: 10.1002/pbc.24076
First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study
Abstract
Background: The standard treatment of fever in chemotherapy-induced neutropenia (FN) includes emergency hospitalization and empirical intravenous antimicrobial therapy. This study determined if first-day step-down to oral outpatient treatment is not inferior to continued standard regarding safety and efficacy in children with low-risk FN.
Procedure: In a randomized controlled non-blinded multicenter study, pediatric patients with FN after non-myeloablative chemotherapy were reassessed after 8-22 hours of inpatient intravenous antimicrobial therapy. Low-risk patients were randomized to first-day step-down to experimental (outpatient, oral amoxicillin plus ciprofloxacin) versus continued standard treatment. Exact non-inferiority tests were used for safety (no serious medical complication; non-inferiority margin of difference, 3.5%) and efficacy (resolution of infection without recurrence, no modification of antimicrobial therapy, no adverse event; 10%).
Results: In 93 (26%) of 355 potentially eligible FN episodes low-risk criteria were fulfilled, and 62 were randomized, 28 to experimental (1 lost to follow-up) and 34 to standard treatment. In intention-to-treat analyses, non-inferiority was not proven for safety [27 of 27 (100%) vs. 33 of 34 (97%; 1 death) episodes; 95% upper confidence border, 6.7%; P = 0.11], but non-inferiority was proven for efficacy [23 of 27 (85%) vs. 26 of 34 (76%) episodes; 95% upper confidence border, 9.4%; P = 0.045]. Per-protocol analyses confirmed these results.
Conclusions: In children with low-risk FN, the efficacy of first-day step-down to oral antimicrobial therapy with amoxicillin and ciprofloxacin in an outpatient setting was non-inferior to continued hospitalization and intravenous antimicrobial therapy. The safety of this procedure, however, was not assessable with sufficient power.
Copyright © 2012 Wiley Periodicals, Inc.
Comment in
-
"Good enough" medicine: noninferiority clinical trials and the management of fever and neutropenia.Pediatr Blood Cancer. 2012 Sep;59(3):415-6. doi: 10.1002/pbc.24119. Epub 2012 Mar 15. Pediatr Blood Cancer. 2012. PMID: 22422727 No abstract available.
Similar articles
-
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.N Engl J Med. 1999 Jul 29;341(5):305-11. doi: 10.1056/NEJM199907293410501. N Engl J Med. 1999. PMID: 10423464 Clinical Trial.
-
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.Med Pediatr Oncol. 2003 Feb;40(2):93-8. doi: 10.1002/mpo.10208. Med Pediatr Oncol. 2003. PMID: 12461792 Clinical Trial.
-
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.J Pediatr Hematol Oncol. 2009 Sep;31(9):635-41. doi: 10.1097/MPH.0b013e3181acd8cd. J Pediatr Hematol Oncol. 2009. PMID: 19684522 Clinical Trial.
-
Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.Ann Pharmacother. 2011 Sep;45(9):1094-102. doi: 10.1345/aph.1Q147. Epub 2011 Aug 23. Ann Pharmacother. 2011. PMID: 21862714 Review.
-
Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.Pediatr Infect Dis J. 2003 Dec;22(12):1138-42. doi: 10.1097/01.inf.0000101993.83884.ed. Pediatr Infect Dis J. 2003. PMID: 14688588 Review.
Cited by
-
Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study.PLoS One. 2023 Aug 2;18(8):e0287233. doi: 10.1371/journal.pone.0287233. eCollection 2023. PLoS One. 2023. PMID: 37531403 Free PMC article.
-
Guidance Statement for the Management of Febrile Neutropenia in Pediatric Patients Receiving Cancer-Directed Therapy in Central America and the Caribbean.JCO Glob Oncol. 2020 Mar;6:508-517. doi: 10.1200/JGO.19.00329. JCO Glob Oncol. 2020. PMID: 32216650 Free PMC article.
-
Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative.Pediatr Blood Cancer. 2013 Jun;60(6):923-7. doi: 10.1002/pbc.24358. Epub 2012 Oct 9. Pediatr Blood Cancer. 2013. PMID: 23047811 Free PMC article.
-
A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.Pediatr Infect Dis J. 2014 Sep;33(9):e219-25. doi: 10.1097/INF.0000000000000326. Pediatr Infect Dis J. 2014. PMID: 24618935 Free PMC article. Clinical Trial.
-
Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.Cochrane Database Syst Rev. 2019 Mar 19;3(3):CD009031. doi: 10.1002/14651858.CD009031.pub2. Cochrane Database Syst Rev. 2019. PMID: 30887505 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous